CURIS INC (CRIS): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:05 ET
- Event date
- 2026-11-12
- Accession no.
- 0001104659-26-127041
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Curis reports third-quarter 2026 results and clinical study updates
Curis reported a third-quarter net loss of $8.1 million and no revenue. The company said its existing cash and October 2026 Private Placement proceeds should fund operations into the first quarter of 2027. It also reported continued enrollment in its TakeAim CLL and TakeAim Lymphoma studies.
- Third-quarter net loss was $8.1 million, or $1.94 per share, compared with $7.7 million, or $9.86 per share, in 2025.
- Cash and cash equivalents totaled $5.0 million as of September 30, 2026.
- The October 2026 Private Placement generated net proceeds of approximately $7.5 million.
- TakeAim CLL enrolled 12 patients, with initial data expected in December 2026.
earningsfinancingproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | tm2629651d1_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | tm2629651d1_ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.